CXCL12 and acute lymphoblastic leukemia: Given that T-ALL chemoresistance and recurrence in the BM correlate with inferior outcomes99, targeting the CXCR4‒CXCL12 axis in the BM TME represents a promising target for emergent T-ALL therapies.